Tetradifon
Based on 1 Customer Validation
Tetradifon is a broad-spectrum organochlorine insecticide and an inhibitor of the mitochondrial oligomycin sensitivity conferring protein (OSCP), which can be used to control a variety of mites. Tetradifon inhibits energy-related activities such as ADP-stimulated respiration, DNP and Mg2+-stimulated ATPase, with an IC50 of 4.5-27 nmoL/mg mitochondrial protein. Tetradifon exerts oligomycin-like activity by inhibiting the oxidative phosphorylation process, inducing oxidative stress and interfering with bone metabolism. Tetradifon is currently mainly used in the research of mitochondrial function regulation, bone remodeling mechanism and nephrotoxicity of environmental pollutants.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 99.78%
- CAS 番号: 116-29-0
- 分子式: C12H6Cl4O2S
- 分子量:356.05
-
保管条件:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
-
溶剤 & 溶解度
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
-
Anti-Infection Compound Library
HY-L002
-
Anti-Aging Compound Library
HY-L034
-
Oxygen Sensing Compound Library
HY-L045
-
Orally Active Compound Library
HY-L061
-
Anti-Parkinson's Disease Compound Library
HY-L085
-
Neurodegenerative Disease-related Compound Library
HY-L086
-
Human Metabolite Library
HY-L123
-
Cuproptosis Compound Library
HY-L133
-
Mitochondrial Toxicity Compound Library
HY-L155
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
-
Mass Spectrometry Human Metabolite Library
HY-L215
-
Environmental Pollutant Compound Library
HY-L247
生物活性
|
Mite |
Tetradifon has a biological mechanism similar to Oligomycin (HY-N6782) and can be reversed by DNP[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Female Wistar rats (190 g, 8-9 weeks, n=12/group)[3]
-
Dosage:2430 mg/kg cumulative (oral in drinking water, 90 days)
-
Administration:Daily oral gavage, 6 and 12 weeks
-
Result:At 12 weeks, increased creatinine/urea levels by 24%/43%, increased glomerular sclerosis rate to 22%, and increased interstitial fibrosis index by 200%.
Decreased renal SOD/GPx activities by 32%/17%, and decreased vitamin C content by 31%.
化学情報
-
CAS 番号 116-29-0
-
性状 Solid
-
分子量 356.05
-
分子式 C12H6Cl4O2S
-
Color White to off-white
-
SMILES
O=S(C1=C(C=C(C(Cl)=C1)Cl)Cl)(C2=CC=C(C=C2)Cl)=O
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
溶剤 & 溶解度
DMSO : 50 mg/mL (140.43 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
純度とドキュメンテーション
-
データシート (277 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
取扱説明書 (2659 KB)
参考文献
[1]. Desaiah D, et al. Tetradifon (tedion R ): a specific inhibitor of Mg 2+ dependent mitochondrial adenosine triphosphatase activity. Life Sci II. 1972 Apr 8;11(7):389-95. [Content Brief]
[2]. Bustamante E, et al. Tetradifon: an oligomycin-like inhibitor of energy-linked activities of rat liver mitochondria. Biochem Biophys Res Commun. 1973 Mar 17;51(2):292-8. [Content Brief]
[3]. Badraoui R, et al. Effect of subchronic exposure to tetradifon on bone remodelling and metabolism in female rat. C R Biol. 2007 Dec;330(12):897-904. [Content Brief]
[4]. Badraoui R, et al. Nephrotoxic effect of tetradifon in rats: a biochemical and histomorphometric study. Exp Toxicol Pathol. 2012 Sep;64(6):645-50. [Content Brief]
[5]. Fatemeh Ganjeizadeh Rohani, et al. Electropolymerized MIP With MWCNTs on Stir Bar Using Multivariate Optimization for Tetradifon Detection in Date. Pharm Nanotechnol. 2019;7(5):404-417. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.8086 mL | 14.0430 mL | 28.0859 mL | 70.2149 mL |
| 5 mM | 0.5617 mL | 2.8086 mL | 5.6172 mL | 14.0430 mL | |
| 10 mM | 0.2809 mL | 1.4043 mL | 2.8086 mL | 7.0215 mL | |
| 15 mM | 0.1872 mL | 0.9362 mL | 1.8724 mL | 4.6810 mL | |
| 20 mM | 0.1404 mL | 0.7021 mL | 1.4043 mL | 3.5107 mL | |
| 25 mM | 0.1123 mL | 0.5617 mL | 1.1234 mL | 2.8086 mL | |
| 30 mM | 0.0936 mL | 0.4681 mL | 0.9362 mL | 2.3405 mL | |
| 40 mM | 0.0702 mL | 0.3511 mL | 0.7021 mL | 1.7554 mL | |
| 50 mM | 0.0562 mL | 0.2809 mL | 0.5617 mL | 1.4043 mL | |
| 60 mM | 0.0468 mL | 0.2340 mL | 0.4681 mL | 1.1702 mL | |
| 80 mM | 0.0351 mL | 0.1755 mL | 0.3511 mL | 0.8777 mL | |
| 100 mM | 0.0281 mL | 0.1404 mL | 0.2809 mL | 0.7021 mL |
Tetradifon 関連分類
HY-119725 関連分類
Powered by Bioz